- Home
- GPRK vs ETON Comparison
GPRK vs ETON Comparison
Compare GPRK & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPRK | ETON |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | Colombia | United States |
| Employees | 382 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 608.0M | 683.7M |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GPRK | ETON |
|---|---|---|
| Price | $10.04 | $26.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $8.50 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 1.4M | 468.4K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | $39.45 | $40.90 |
| Revenue Next Year | N/A | $47.23 |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $5.75 | $13.09 |
| 52 Week High | $10.34 | $27.19 |
Technical Indicators
Market Signals| Indicator | GPRK | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 61.05 | 72.12 |
| Support Level | $7.84 | $16.38 |
| Resistance Level | $10.16 | N/A |
| Average True Range (ATR) | 0.53 | 1.28 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 89.12 | 90.65 |
Price Performance
Historical ComparisonAbout GPRK Geopark Ltd
GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.